The DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.
Novobiocin and Additional Inhibitors of the Hsp90 C-Terminal Nucleotide- binding Pocket
Open accessAbstract
The 90 kDa heat shock proteins (Hsp90), which are integrally involved in cell signaling, proliferation, and survival, are ubiquitously expressed in cells. Many proteins in tumor cells are dependent upon the Hsp90 protein folding machinery for their stability, refolding, and maturation. Inhibition of Hsp90 uniquely targets client proteins associated with all six hallmarks of cancer. Thus, Hsp90 has emerged as a promising target for the treatment of cancer. Hsp90 exists as a homodimer, which contains three domains. The N-terminal domain contains an ATP-binding site that binds the natural products geldanamycin and radicicol. The middle domain is highly charged and has high affinity for co-chaperones and client proteins. Initial studies by Csermely and co-workers suggested a second ATP-binding site in the C-terminus of Hsp90. This C-terminal nucleotide binding pocket has been shown to not only bind ATP, but cisplatin, novobiocin, epilgallocatechin-3-gallate (EGCG) and taxol. The coumarin antibiotics novobiocin, clorobiocin, and coumermycin A1 were isolated from several streptomyces strains and exhibit potent activity against Gram-positive bacteria. These compounds bind type II topoisomerases, including DNA gyrase, and inhibit the enzyme-catalyzed hydrolysis of ATP. As a result, novobiocin analogues have garnered the attention of numerous researchers as an attractive agent for the treatment of bacterial infection. Novobiocin was reported to bind weakly to the newly discovered Hsp90 C-terminal ATP binding site ( approximately 700 M in SkBr3 cells) and induce degradation of Hsp90 client proteins. Structural modification of this compound has led to an increase of 1000-fold in activity in anti-proliferative assays. Recent studies of structure-activity relationship (SAR) by Renoir and co-workers highlighted the crucial role of the C-4 and/or C-7 positions of the coumarin and removal of the noviose moiety, which appeared to be essential for degradation of Hsp90 client proteins. Unlike the N-terminal ATP binding site, there is no reported co-crystal structure of Hsp90 C-terminus bound to any inhibitor. The Hsp90 C-terminal domain, however, is known to contain a conserved pentapeptide sequence (MEEVD) which is recognized by co-chaperones. Cisplatin is a platinum-containing chemotherapeutic used to treat various types of cancers, including testicular, ovarian, bladder, and small cell lung cancer. Most notably, cisplatin coordinates to DNA bases, resulting in cross-linked DNA, which prohibits rapidly dividing cells from duplicating DNA for mitosis. Itoh and co-workers reported that cisplatin decreases the chaperone activity of Hsp90. This group applied bovine brain cytosol to a cisplatin affinity column, eluted with cisplatin and detected Hsp90 in the eluent. Subsequent experiments indicated that cisplatin exhibits high affinity for Hsp90. Moreover Csermely and co-workers determined that the cisplatin binding site is located proximal to the C-terminal ATP binding site. EGCG is one of the active ingredients found in green tea. EGCG is known to inhibit the activity of many Hsp90-dependent client proteins, including telomerase, several kinases, and the aryl hydrocarbon receptor (AhR). Recently Gasiewicz and co-workers reported that EGCG manifests its antagonistic activity against AhR through binding Hsp90. Similar to novobiocin, EGCG was shown to bind the C-terminus of Hsp90. Unlike previously identified N-terminal Hsp90 inhibitors, EGCG does not appear to prevent Hsp90 from forming multiprotein complexes. Studies are currently underway to determine whether EGCG competes with novobiocin or cisplatin binding. Taxol, a well-known drug for the treatment of cancer, is responsible for the stabilization of microtubules and the inhibition of mitosis. Previous studies have shown that taxol induces the activation of kinases and transcription factors, and mimics the effect of bacterial lipopolysaccharide (LPS), an attribute unrelated to its tubulin-binding properties. Rosen and co-workers prepared a biotinylated taxol derivative and performed affinity chromatography experiments with lysates from both mouse brain and macrophage cell lines. These studies led to identification of two chaperones, Hsp70 and Hsp90, by mass spectrometry. In contrast to typical Hsp90-binding drugs, taxol exhibits a stimulatory response. Recently it was reported that the geldanamycin derivative 17-AAG behaves synergistically with taxol-induced apoptosis. This review describes the different C-terminal inhibitors of Hsp90, with specific emphasis on structure-activity relationship studies of novobiocin and their effects on anti-proliferative activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
Lindquist, S., & Craig, E. A. (1988) · Annual Review of Genetics · doi:10.1146/annurev.ge.22.120188.003215 · Cited by 5,284
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., & McPhail, A. T. (1971) · Journal of the American Chemical Society · doi:10.1021/ja00738a045 · Cited by 4,073
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 2,481
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
Cobb, M. H., & Goldsmith, E. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.25.14843 · Cited by 1,719
Pratt, W. B., & Toft, D. O. (2003) · Experimental Biology and Medicine · doi:10.1177/153537020322800201 · Cited by 1,483
Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1997) · Cell · doi:10.1016/s0092-8674(00)80314-1 · Cited by 1,265
The crystal structure of the asymmetric GroEL–GroES–(ADP)7 chaperonin complex
Xu, Z., Horwich, A. L., & Sigler, P. B. (1997) · Nature · doi:10.1038/41944 · Cited by 1,239
Aubert, G., & Lansdorp, P. M. (2008) · Physiological Reviews · doi:10.1152/physrev.00026.2007 · Cited by 1,188
Structure of TPR Domain–Peptide Complexes
Scheufler, C., Brinker, A., Bourenkov, G., Pegoraro, S., Moroder, L., Bartunik, H., Hartl, F. U., & Moarefi, I. (2000) · Cell · doi:10.1016/s0092-8674(00)80830-2 · Cited by 1,188
Folding of Newly Translated Proteins In Vivo: The Role of Molecular Chaperones
Frydman, J. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.603 · Cited by 1,173
The MAP kinase cascade is essential for diverse signal transduction pathways
Nishida, E., & Gotoh, Y. (1993) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(93)90019-j · Cited by 1,076
The 90-kDa Molecular Chaperone Family
Csermely, P., Schnaider, T., So″ti, C., Prohászka, Z., & Nardai, G. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00013-8 · Cited by 1,028
Role of Akt Signaling in Vascular Homeostasis and Angiogenesis
Shiojima, I., & Walsh, K. (2002) · Circulation Research · doi:10.1161/01.res.0000022200.71892.9f · Cited by 1,012
Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004
MAP kinase kinase kinase, MAP kinase kinase and MAP kinase
Marshall, C. J. (1994) · Current Opinion in Genetics & Development · doi:10.1016/0959-437x(94)90095-7 · Cited by 999
Modulation of Akt kinase activity by binding to Hsp90
Sato, S., Fujita, N., & Tsuruo, T. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.170276797 · Cited by 967
Crystal structure of an Hsp90–nucleotide–p23/Sba1 closed chaperone complex
Ali, M. M. U., Roe, S. M., Vaughan, C. K., Meyer, P., Panaretou, B., Piper, P. W., Prodromou, C., & Pearl, L. H. (2006) · Nature · doi:10.1038/nature04716 · Cited by 962
MAPKs: new JNK expands the group
Davis, R. J. (1994) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(94)90132-5 · Cited by 944
Direct control of the Forkhead transcription factor AFX by protein kinase B
Kops, G. J. P. L., Ruiter, N. D. D., De Vries-Smits, A. M. M., Powell, D. R., Bos, J. L., & Burgering, B. M. T. (1999) · Nature · doi:10.1038/19328 · Cited by 882
Warrick, J. M., Chan, H. Y. E., Gray-Board, G. L., Chai, Y., Paulson, H. L., & Bonini, N. M. (1999) · Nature Genetics · doi:10.1038/70532 · Cited by 830
Alonso, A. D. C., Zaidi, T., Novak, M., Grundke-Iqbal, I., & Iqbal, K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121119298 · Cited by 827
Heat-shock protein 90, a chaperone for folding and regulation
Picard, D. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/pl00012491 · Cited by 796
ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo
Panaretou, B., Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1998) · The EMBO Journal · doi:10.1093/emboj/17.16.4829 · Cited by 735
SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells
Hamamoto, R., Furukawa, Y., Morita, M., Iimura, Y., Silva, F. P., Li, M., Yagyu, R., & Nakamura, Y. (2004) · Nature Cell Biology · doi:10.1038/ncb1151 · Cited by 731
DNA Gyrase: Structure and Function
Reece, R. J., & Maxwell, A. (1991) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409239109114072 · Cited by 728
Protein kinase cascades activated by stress and inflammatory cytokines
Kyriakis, J. M., & Avruch, J. (1996) · BioEssays · doi:10.1002/bies.950180708 · Cited by 709
Hsp90 inhibitors as novel cancer chemotherapeutic agents
Neckers, L. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02316-x · Cited by 677
Basso, A. D., Solit, D. B., Chiosis, G., Giri, B., Tsichlis, P., & Rosen, N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206322200 · Cited by 628
Hsp90 & Co. – a holding for folding
Buchner, J. (1999) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(99)01373-0 · Cited by 628
Hsp90 isoforms: functions, expression and clinical importance
Subbarao Sreedhar, A., Kalmár, É., Csermely, P., & Shen, Y.-F. (2004) · FEBS Letters · doi:10.1016/s0014-5793(04)00229-7 · Cited by 620
In Vivo Function of Hsp90 Is Dependent on ATP Binding and ATP Hydrolysis
Obermann, W. M. J., Sondermann, H., Russo, A. A., Pavletich, N. P., & Hartl, F. U. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.4.901 · Cited by 601
Eustace, B. K., Sakurai, T., Stewart, J. K., Yimlamai, D., Unger, C., Zehetmeier, C., Lain, B., Torella, C., Henning, S. W., Beste, G., et al. (2004) · Nature Cell Biology · doi:10.1038/ncb1131 · Cited by 590
Heat shock protein 90 as a molecular target for cancer therapeutics
Isaacs, J. S., Xu, W., & Neckers, L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00029-1 · Cited by 577
Activation of the ATPase Activity of Hsp90 by the Stress-Regulated Cochaperone Aha1
Panaretou, B., Siligardi, G., Meyer, P., Maloney, A., Sullivan, J. K., Singh, S., Millson, S. H., Clarke, P. A., Naaby-Hansen, S., Stein, R., et al. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00785-2 · Cited by 542
Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal
Tsuruo, T., Naito, M., Tomida, A., Fujita, N., Mashima, T., Sakamoto, H., & Haga, N. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01345.x · Cited by 502
Marcu, M. G., Chadli, A., Bouhouche, I., Catelli, M., & Neckers, L. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003701200 · Cited by 502
Prodromou, C., Panaretou, B., Chohan, S., Siligardi, G., O'Brien, R., Ladbury, J. E., Roe, S. M., Piper, P. W., & Pearl, L. H. (2000) · The EMBO Journal · doi:10.1093/emboj/19.16.4383 · Cited by 492
Meyer, P., Prodromou, C., Hu, B., Vaughan, C., Roe, S. M., Panaretou, B., Piper, P. W., & Pearl, L. H. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00065-0 · Cited by 491
Targeting the c-Met Signaling Pathway in Cancer
Peruzzi, B., & Bottaro, D. P. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0818 · Cited by 448
Mutations causing neurodegenerative tauopathies
Goedert, M., & Jakes, R. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.08.007 · Cited by 438
Sturgill, T. W., & Wu, J. (1991) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(97)90012-4 · Cited by 436
Molecular Chaperones—Cellular Machines for Protein Folding
Walter, S., & Buchner, J. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20020402)41:7<1098::aid-anie1098>3.0.co;2-9 · Cited by 436
Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperones
Prodromou, C. (1999) · The EMBO Journal · doi:10.1093/emboj/18.3.754 · Cited by 425
Novobiocin and Related Coumarins and Depletion of Heat Shock Protein 90-Dependent Signaling Proteins
Marcu, M. G., Schulte, T. W., & Neckers, L. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.242 · Cited by 405
Neckers, L., & Ivy, S. P. (2003) · Current Opinion in Oncology · doi:10.1097/00001622-200311000-00003 · Cited by 400
Cellular and molecular determinants of cisplatin resistance
Perez, R. P. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00227-5 · Cited by 384
Heat shock proteins as emerging therapeutic targets
Sõti, C., Nagy, E., Giricz, Z., Vígh, L., Csermely, P., & Ferdinandy, P. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706396 · Cited by 380
Targeting multiple signal transduction pathways through inhibition of Hsp90
Zhang, H., & Burrows, F. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0549-9 · Cited by 377
Modifications of DNA by platinum complexes
Brabec, V., & Kasparkova, J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.04.006 · Cited by 373
The hsp90-related Protein TRAP1 Is a Mitochondrial Protein with Distinct Functional Properties
Felts, S. J., Owen, B. A. L., Nguyen, P., Trepel, J., Donner, D. B., & Toft, D. O. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.5.3305 · Cited by 370
Heat shock protein 90: The cancer chaperone
Neckers, L. (2007) · Journal of Biosciences · doi:10.1007/s12038-007-0051-y · Cited by 365
RNA-mediated response to heat shock in mammalian cells
Shamovsky, I., Ivannikov, M., Kandel, E. S., Gershon, D., & Nudler, E. (2006) · Nature · doi:10.1038/nature04518 · Cited by 361
&cestflwr; The Hsp90 family of proteins in Arabidopsis thaliana
Krishna, P., & Gloor, G. (2001) · Cell Stress & Chaperones · doi:10.1379/1466-1268(2001)006<0238:thfopi>2.0.co;2 · Cited by 359
Lewis, R. J., Singh, O. M., Smith, C. V., Skarzynski, T., Maxwell, A., Wonacott, A. J., & Wigley, D. B. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00483.x · Cited by 335
The Hsp90 chaperone complex as a novel target for cancer therapy
Goetz, M. P., Toft, D. O., Ames, M. M., & Erlichman, C. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg316 · Cited by 334
Analysis of phosphorylation of human heat shock factor 1 in cells experiencing a stress
Guettouche, T., Boellmann, F., Lane, W. S., & Voellmy, R. (2005) · BMC Biochemistry · doi:10.1186/1471-2091-6-4 · Cited by 318
Brown, M. A., Sims, R. J., Gottlieb, P. D., & Tucker, P. W. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-26 · Cited by 313
Ali, J. A., Jackson, A. P., Howells, A. J., & Maxwell, A. (1993) · Biochemistry · doi:10.1021/bi00061a033 · Cited by 303
Structure of an Hsp90-Cdc37-Cdk4 Complex
Vaughan, C. K., Gohlke, U., Sobott, F., Good, V. M., Ali, M. M. U., Prodromou, C., Robinson, C. V., Saibil, H. R., & Pearl, L. H. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.07.016 · Cited by 293
Shared Actions of Endotoxin and Taxol on TNF Receptors and TNF release
Ding, A. H., Porteu, F., Sanchez, E., & Nathan, C. F. (1990) · Science · doi:10.1126/science.1970196 · Cited by 281
Solit, D. B., Basso, A. D., Olshen, A. B., Scher, H. I., & Rosen, N. X. (2003) · PubMed · Cited by 277
The mitogen-activated protein kinase activator
Ahn, N. G., Seger, R., & Krebs, E. G. (1992) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(92)90131-u · Cited by 276
Luo, W., Dou, F., Rodina, A., Chip, S., Kim, J., Zhao, Q., Moulick, K., Aguirre, J., Wu, N., Greengard, P., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701055104 · Cited by 274
Stable Association of hsp90 and p23, but Not hsp70, with Active Human Telomerase
Forsythe, H. L., Jarvis, J. L., Turner, J. W., Elmore, L. W., & Holt, S. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100055200 · Cited by 248
Two chaperone sites in Hsp90 differing in substrate specificity and ATP dependence
Scheibel, T., Weikl, T., & Buchner, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1495 · Cited by 243
Novobiocin: Redesigning a DNA Gyrase Inhibitor for Selective Inhibition of Hsp90
Burlison, J. A., Neckers, L., Smith, A. B., Maxwell, A., & Blagg, B. S. J. (2006) · Journal of the American Chemical Society · doi:10.1021/ja065793p · Cited by 242
Self-citationThe Assembly of Progesterone Receptor-hsp90 Complexes Using Purified Proteins
Kosano, H., Stensgard, B., Charlesworth, M. C., McMahon, N., & Toft, D. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32973 · Cited by 240
Lotz, G. P., Lin, H., Harst, A., & Obermann, W. M. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212761200 · Cited by 236
Hsp90: the vulnerable chaperone
Chiosis, G., Vilenchik, M., Kim, J., & Solit, D. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03245-3 · Cited by 229
The molecular chaperone Hsp90 plays a role in the assembly and maintenance of the 26S proteasome
Imai, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg349 · Cited by 228
Specific Binding of Tetratricopeptide Repeat Proteins to the C-terminal 12-kDa Domain of hsp90
Young, J. C., Obermann, W. M. J., & Hartl, F. U. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18007 · Cited by 227
Clinical Development of 17-Allylamino, 17-Demethoxygeldanamycin
Sausville, E., Tomaszewski, J., & Ivy, P. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481831 · Cited by 225
Recent Developments in the Field of Anticancer Platinum Complexes
Galanski, M. S. (2006) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489206777442287 · Cited by 223
A Nucleotide-dependent Molecular Switch Controls ATP Binding at the C-terminal Domain of Hsp90
Söti, C., Rácz, A., & Csermely, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m105568200 · Cited by 212
Holdgate, G. A., Tunnicliffe, A., Ward, W. H. J., Weston, S. A., Rosenbrock, G., Barth, P. T., Taylor, I. W. F., Pauptit, R. A., & Timms, D. (1997) · Biochemistry · doi:10.1021/bi970294+ · Cited by 209
Heat shock protein 90 mediates macrophage activation by Taxol and bacterial lipopolysaccharide
Byrd, C. A., Bornmann, W., Erdjument-Bromage, H., Tempst, P., Pavletich, N., Rosen, N., Nathan, C. F., & Ding, A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5645 · Cited by 201
Heat-induced Chaperone Activity of HSP90
Yonehara, M., Minami, Y., Kawata, Y., Nagai, J., & Yahara, I. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.5.2641 · Cited by 195
A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons
Zheng, Y., Kesavapany, S., Gravell, M., Hamilton, R. S., Schubert, M., Amin, N., Albers, W., Grant, P., & Pant, H. C. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600441 · Cited by 189
Blagg, B. S. J., & Kerr, T. D. (2006) · Medicinal Research Reviews · doi:10.1002/med.20052 · Cited by 189
Self-citationChen, S., Sullivan, W. P., Toft, D. O., & Smith, D. F. (1998) · Cell Stress & Chaperones · doi:10.1379/1466-1268(1998)003<0118:diopat>2.3.co;2 · Cited by 188
Non-Aβ Component of Alzheimer's Disease Amyloid (NAC) Revisited
Culvenor, J. G., McLean, C. A., Cutt, S., Campbell, B. C. V., Maher, F., Jäkälä, P., Hartmann, T., Beyreuther, K., Masters, C. L., & Li, Q.-X. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65220-0 · Cited by 180
Mechanism of Dimer Formation of the 90‐kDa Heat‐Shock Protein
Nemoto, T., Ohara‐Nemoto, Y., Ota, M., Takagi, T., & Yokoyama, K. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.001_1.x · Cited by 176
Hsp90–Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis
Zhang, R., Luo, D., Miao, R., Bai, L., Ge, Q., Sessa, W. C., & Min, W. (2005) · Oncogene · doi:10.1038/sj.onc.1208548 · Cited by 174
Hsp90 Inhibitors Identified from a Library of Novobiocin Analogues
Yu, X. M., Shen, G., Neckers, L., Blake, H., Holzbeierlein, J., Cronk, B., & Blagg, B. S. J. (2005) · Journal of the American Chemical Society · doi:10.1021/ja0535864 · Cited by 172
Self-citationWebb, C. P., Hose, C. D., Koochekpour, S., Jeffers, M., Oskarsson, M. K., Sausville, E. A., Monks, A. P., & Woude, G. F. V. (2000) · PubMed · Cited by 168
Palermo, C. M., Westlake, C. A., & Gasiewicz, T. A. (2005) · Biochemistry · doi:10.1021/bi047433p · Cited by 166
Inhibition of Hsp90: a new strategy for inhibiting protein kinases
Sreedhar, A. S., Sőti, C., & Csermely, P. (2003) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2003.11.027 · Cited by 160
Allan, R. K., Mok, D., Ward, B. K., & Ratajczak, T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512406200 · Cited by 159
The glucose-regulated protein grp94 is related to heat shock protein hsp90
Sorger, P. K., & Pelham, H. R. B. (1987) · Journal of Molecular Biology · doi:10.1016/0022-2836(87)90380-9 · Cited by 159
Constantly Updated Knowledge of Hsp90
Terasawa, K., Minami, M., & Minami, Y. (2005) · The Journal of Biochemistry · doi:10.1093/jb/mvi056 · Cited by 156
High constitutive expression of heat shock protein 90α in human acute leukemia cells
Yufu, Y., Nishimura, J., & Nawata, H. (1992) · Leukemia Research · doi:10.1016/0145-2126(92)90008-u · Cited by 155
17AAG: low target binding affinity and potent cell activity--finding an explanation.
Chiosis, G., Huezo, H., Rosen, N. X., Mimnaugh, E. G., Whitesell, L. J., & Neckers, L. (2003) · PubMed · Cited by 149
Binding of ATP to Heat Shock Protein 90
Garnier, C., Lafitte, D., Tsvetkov, P. O., Barbier, P., Leclerc, J., Millot, J., Briand, C. M., Makarov, A. А., CATELLI, M. G., & Peyrot, V. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111874200 · Cited by 145
Bras, G. L., Radanyi, C., Peyrat, J., Brion, J., Alami, M., Marsaud, V., Stella, B., & Renoir, J. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0707774 · Cited by 145
Hsp90: a chaperone for protein folding and gene regulation
Zhao, R., & Houry, W. A. (2005) · Biochemistry and Cell Biology · doi:10.1139/o05-158 · Cited by 144
The role of heat-shock proteins as molecular chaperones
Welch, W. J. (1991) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(91)90125-i · Cited by 142
Burlison, J. A., Avila, C., Vielhauer, G. A., Lubbers, D. J., Holzbeierlein, J. M., & Blagg, B. S. J. (2008) · The Journal of Organic Chemistry · doi:10.1021/jo702191a · Cited by 138
Self-citationLouvion, J.-F., Warth, R., & Picard, D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13937 · Cited by 135
c-Met and hepatocyte growth factor: Potential as novel targets in cancer therapy
Sattler, M., & Salgia, R. (2007) · Current Oncology Reports · doi:10.1007/s11912-007-0005-4 · Cited by 130
The Middle Domain of Hsp90 Acts as a Discriminator between Different Types of Client Proteins
Hawle, P., Siepmann, M., Harst, A., Siderius, M., Reusch, H. P., & Obermann, W. M. J. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02188-05 · Cited by 127
Structural Studies on the Co-chaperone Hop and Its Complexes with Hsp90
Onuoha, S. C., Coulstock, E. T., Grossmann, J. G., & Jackson, S. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.02.013 · Cited by 127
Identification of Genes That Mediate Sensitivity to Cisplatin
Niedner, H., Christen, R. D., Lin, X., Kondo, A., & Howell, S. B. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.6.1153 · Cited by 126
Kim, H. R., Kang, H. S., & Kim, H. D. (1999) · IUBMB Life · doi:10.1080/713803536 · Cited by 125
Harst, A., Lin, H.-Y., & Obermann, W. (2005) · Biochemical Journal · doi:10.1042/bj20041283 · Cited by 121
Lavoie, J. N., Rivard, N., L’Allemain, G., & Pouysségur, J. (1996) · Springer eBooks · doi:10.1007/978-1-4615-5873-6_5 · Cited by 106
Cunningham, C. N., Krukenberg, K., & Agard, D. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800046200 · Cited by 105
The charged region of Hsp90 modulates the function of the N-terminal domain
Scheibel, T., Siegmund, H. I., Jaenicke, R., Ganz, P., Lilie, H., & Büchner, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1297 · Cited by 105
Sőti, C., Vermes, Á., Haystead, T., & Csermely, P. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03610.x · Cited by 104
Novobiocin Induces a Distinct Conformation of Hsp90 and Alters Hsp90−Cochaperone−Client Interactions
Yun, B.-G., Huang, W., Leach, N., Hartson, S. D., & Matts, R. L. (2004) · Biochemistry · doi:10.1021/bi0497998 · Cited by 102
Hsp90 as a Target for Drug Development
Chaudhury, S., Welch, T. R., & Blagg, B. S. J. (2006) · ChemMedChem · doi:10.1002/cmdc.200600112 · Cited by 102
Self-citationSahara, N., Maeda, S., Yoshiike, Y., Mizoroki, T., Yamashita, S., Murayama, M., Park, J. ‐., Saito, Y., Murayama, S., & Takashima, A. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21417 · Cited by 98
Grammatikakis, N., Vultur, A., Ramana, C. V., Siganou, A., Schweinfest, C. W., Watson, D. K., & Raptis, L. H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109200200 · Cited by 97
Murphy, P. J. M., Kanelakis, K. C., Galigniana, M. D., Morishima, Y., & Pratt, W. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103773200 · Cited by 92
Kim, S., Yoon, J., Lee, S.-H., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411908200 · Cited by 91
Tauopathies: recent insights into old diseases.
Delacourte, A. (2005) · PubMed · Cited by 88
Caplan, A. J. (2003) · Cell Stress and Chaperones · Cited by 86
Hartson, S. D., Thulasiraman, V., Huang, W., Whitesell, L. J., & Matts, R. L. (1999) · Biochemistry · doi:10.1021/bi983027s · Cited by 84
Millson, S. H., Truman, A. W., Rácz, Á., Hu, B., Panaretou, B., Nuttall, J. M., Mollapour, M., Sőti, C., & Piper, P. W. (2007) · FEBS Journal · doi:10.1111/j.1742-4658.2007.05974.x · Cited by 83
A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90
Itoh, H., Ogura, M., Komatsuda, A., Wakui, H., MIURA, A. B., & Tashima, Y. (1999) · Biochemical Journal · doi:10.1042/bj3430697 · Cited by 83
New agents in cancer clinical trials
Adams, J., & Elliott, P. J. (2000) · Oncogene · doi:10.1038/sj.onc.1204088 · Cited by 80
Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent ErbB2
Xu, W., Mimnaugh, E. G., Kim, J.-S., Trepel, J. B., & Neckers, L. Μ. (2002) · Cell Stress and Chaperones · doi:10.1379/1466-1268(2002)007<0091:hngrti>2.0.co;2 · Cited by 79
Biochemical and Structural Studies of the Interaction of Cdc37 with Hsp90
Zhang, W., Hirshberg, M., McLaughlin, S. H., Lazar, G. A., Grossmann, J. G., Nielsen, P. R., Sobott, F., Robinson, C. V., Jackson, S., & Laue, E. D. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.05.007 · Cited by 79
Molecular mechanisms of durg inhibition of DNA gyrase
Lewis, R. J., Tsai, F., & Wigley, D. B. (1996) · BioEssays · doi:10.1002/bies.950180810 · Cited by 75
Miyata, Y., Ikawa, Y., Shibuya, M., & Nishida, E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010944200 · Cited by 73
Recent Advances in the Study of hsp90 Structure and Mechanism of Action
Toft, D. O. (1998) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(98)00060-5 · Cited by 70
Breast cancer metastasis suppressor 1 (BRMS1) is stabilized by the Hsp90 chaperone
Hurst, D. R., Mehta, A., Moore, B. P., Phadke, P. A., Meehan, W. J., Accavitti, M. A., Shevde, L. A., Hopper, J. E., Xie, Y., Welch, D. R., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.08.005 · Cited by 69
Apo‐Hsp90 coexists in two open conformational states in solution
Bron, P., Giudice, E., Rolland, J., Buey, R. M., Barbier, P., Díaz, J. F., Peyrot, V., Thomas, D., & Garnier, C. (2008) · Biology of the Cell · doi:10.1042/bc20070149 · Cited by 68
The Heat Shock Protein 90-Targeting Drug Cisplatin Selectively Inhibits Steroid Receptor Activation
Rosenhagen, M. C., Sőti, C., Schmidt, U., Wochnik, G. M., Hartl, F. U., Holsboer, F., Young, J. C., & Rein, T. (2003) · Molecular Endocrinology · doi:10.1210/me.2003-0141 · Cited by 62
Tau Protein Phosphorylation as a Therapeutic Target in Alzheimers Disease
Lau, L., Schachter, J. B., Seymour, P. A., & Sanner, M. A. (2002) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026024607526 · Cited by 62
Correlation of Amyloid Fibril β‐Structure with the Unfolded State of α‐Synuclein
Kim, H., Heise, H., Fernández, C. O., Baldus, M., & Zweckstetter, M. (2007) · ChemBioChem · doi:10.1002/cbic.200700366 · Cited by 61
Histone deacetylase inhibitors for epigenetic therapy of cancer
Monneret, C. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328012a5db · Cited by 59
CYTOCHROME P450 UBIQUITINATION: Branding for the Proteolytic Slaughter?
Correia, M. A., Sadeghi, S. J., & Mundo-Paredes, E. (2004) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.100127 · Cited by 58
Liao, C., Hu, B., Arno, M. J., & Panaretou, B. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.030494 · Cited by 57
Huang, R.-Y., Eddy, M., Vujcic, M., & Kowalski, D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4093 · Cited by 56
Laurin, P., Ferroud, D., Schio, L., Klich, M., Dupuis‐Hamelin, C., Mauvais, P., Lassaigne, P., Bonnefoy, A., & Musicki, B. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00492-8 · Cited by 55
Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion
Xie, Q. R., Gao, C.-F., Shinomiya, N., Sausville, E. A., Hay, R. V., Gustafson, M. F., Shen, Y., Wenkert, D., & Woude, G. F. V. (2005) · Oncogene · doi:10.1038/sj.onc.1208499 · Cited by 54
Frankenberg-Schwager, M., Kirchermeier, D., Greif, G., Bär, K., Becker, M., & Frankenberg, D. (2005) · Toxicology · doi:10.1016/j.tox.2005.04.015 · Cited by 52
Temperature-sensitive mutants of hsp82 of the budding yeast Saccharomyces cerevisiae
Kimura, Y., Matsumoto, S., & Yahara, I. (1994) · Molecular and General Genetics MGG · doi:10.1007/bf00285275 · Cited by 51
Analysis of Hsp90 Cochaperone Interactions Reveals a Novel Mechanism for TPR Protein Recognition
Chadli, A., Bruinsma, E. S., Stensgard, B. A., & Toft, D. O. (2008) · Biochemistry · doi:10.1021/bi7023332 · Cited by 35
A Library of Noviosylated Coumarin Analogues
Huang, Y.-T., & Blagg, B. S. J. (2007) · The Journal of Organic Chemistry · doi:10.1021/jo062083t · Cited by 24
Self-citationKim, S. H., Kim, D., Jung, G. S., Um, J. H., Chung, B., & Kang, C. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1229 · Cited by 24
Matsumoto, S., Tanaka, E., Nemoto, T., Ono, T., Takagi, T., Imai, J., Kimura, Y., Yahara, I., Kobayakawa, T., Ayuse, T., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203038200 · Cited by 21
Jibard, N., Meng, X., Leclerc, P., Rajkowski, K. M., Fortin, D., Schweizer-Groyer, G., CATELLI, M. G., Baulieu, É.-É., & Cadepond, F. (1999) · Experimental Cell Research · doi:10.1006/excr.1998.4375 · Cited by 19
PEPIN, K., Momose, F., Ishida, N., & Nagata, K. (2001) · Journal of Veterinary Medical Science · doi:10.1292/jvms.63.115 · Cited by 13
Substitution of only two residues of human Hsp90α causes impeded dimerization of Hsp90β
Kobayakawa, T., Yamada, S., Mizuno, A., & Nemoto, T. (2008) · Cell Stress and Chaperones · doi:10.1007/s12192-008-0017-5 · Cited by 12
Cited by
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Targeting the dynamic HSP90 complex in cancer
Trepel, J., Mollapour, M., Giaccone, G., & Neckers, L. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2887 · Cited by 1,514
Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
Neckers, L., & Workman, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1000 · Cited by 891
The HSP90 Family: Structure, Regulation, Function, and Implications in Health and Disease
Hoter, A., El-Sabban, M. E., & Naim, H. Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092560 · Cited by 693
Coumarins: Old Compounds with Novel Promising Therapeutic Perspectives
Riveiro, M., De Kimpe, N., Moglioni, A., Vazquez, R., Monczor, F., Shayo, C., & Davio, C. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790936284 · Cited by 448
Metadata
- Authors
- Donnelly, A., & Blagg, B.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2008-11-01
- Volume
- 15
- Issue
- 26
- Pages
- 2702-2717
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2022254839
- Cited by
- 313
- References
- 151
- FWCI
- 9.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.